Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) is now available.
Recordati reported strong financial performance in the first half of 2025, with consolidated net revenues increasing by 11.7% to €1,323.8 million. The company signed a license and supply agreement with Amarin for the commercialization of Vazkepa® in Europe, enhancing its cardiovascular portfolio. Despite adverse exchange rate impacts, Recordati maintained its financial targets for 2025, demonstrating robust execution and strategic growth in both its Specialty & Primary Care and Rare Diseases sectors.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR51.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. is a pharmaceutical company based in Milan, Italy. It operates in the Specialty & Primary Care and Rare Diseases sectors, focusing on therapeutic areas such as cardiovascular, gastrointestinal, endocrinology, onco-hematology, and metabolic diseases. The company is committed to expanding its market presence in Europe and the United States.
Average Trading Volume: 291,915
Technical Sentiment Signal: Strong Buy
Current Market Cap: €11.07B
Learn more about REC stock on TipRanks’ Stock Analysis page.